
Operations Office

Telephone (507) 284-2172



Date: October 28, 2005

To: NCCCTG Primary Clinical Research Associates

From: Patricia A. Mann
Protocol Development Coordinator

Re: N04C2, An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR[®] Depot) for Symptomatic Ascites in Cancer Patients

The above study is now active.

A protocol and forms packet are enclosed. You may submit this protocol to your IRB for approval.

Specimen kits are being assembled and will be available to order on November 9, 2005.

Please note that your NCCTG site must have IRB approval and must have a patient enrolling in the trial before study medication will be provided. The sodium chloride placebo will not be provided by Novartis or the NCCTG research base.

Please note that this study was approved by the National Cancer Institute on June 16, 2005.

If you have any questions, please feel free to contact me.

Enclosure